LLY

1,019.18

+2.96%↑

JNJ

230.3

+2.26%↑

ABBV

208.61

+0.24%↑

UNH

401.79

+1.9%↑

AZN

186.75

+0.93%↑

LLY

1,019.18

+2.96%↑

JNJ

230.3

+2.26%↑

ABBV

208.61

+0.24%↑

UNH

401.79

+1.9%↑

AZN

186.75

+0.93%↑

LLY

1,019.18

+2.96%↑

JNJ

230.3

+2.26%↑

ABBV

208.61

+0.24%↑

UNH

401.79

+1.9%↑

AZN

186.75

+0.93%↑

LLY

1,019.18

+2.96%↑

JNJ

230.3

+2.26%↑

ABBV

208.61

+0.24%↑

UNH

401.79

+1.9%↑

AZN

186.75

+0.93%↑

LLY

1,019.18

+2.96%↑

JNJ

230.3

+2.26%↑

ABBV

208.61

+0.24%↑

UNH

401.79

+1.9%↑

AZN

186.75

+0.93%↑

Inicio・Lista de Acciones・Ardelyx Inc

Ardelyx Inc

Abierto

SectorSanidad

6.37 -3.78

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

6.12

Máximo

6.61

Métricas clave
By Trading Economics
Ingresos	-37M -38M
Ventas	-31M 94M
BPA	-0.15
Margen de beneficios	-39.805
Empleados	489
EBITDA	-42M -32M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+151.13% upside

Dividendos
By Dow Jones
Próximas Ganancias	3 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	164M 1.6B
Apertura anterior	10.15
Cierre anterior	6.37

Noticias sobre sentimiento de mercado

By Acuity

26%

74%

64 / 346 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

3.62 / 3.95 Soporte y Resistencia

Ardelyx Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 may 2026, 22:50 UTC

Ganancias

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 may 2026, 22:49 UTC

Ganancias

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 may 2026, 22:32 UTC

Ganancias

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 may 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 may 2026, 22:57 UTC

Charlas de Mercado

Ganancias

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 may 2026, 22:26 UTC

Ganancias

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 may 2026, 22:25 UTC

Ganancias

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 may 2026, 22:25 UTC

Ganancias

Aristocrat Leisure Interim Dividend A$0.50/Security

12 may 2026, 22:24 UTC

Ganancias

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 may 2026, 22:23 UTC

Ganancias

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 may 2026, 22:23 UTC

Ganancias

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 may 2026, 22:19 UTC

Ganancias

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 may 2026, 22:14 UTC

Ganancias

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 may 2026, 22:14 UTC

Ganancias

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 may 2026, 22:13 UTC

Ganancias

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 may 2026, 22:12 UTC

Ganancias

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 may 2026, 22:12 UTC

Ganancias

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 may 2026, 22:11 UTC

Ganancias

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 may 2026, 22:11 UTC

Ganancias

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 may 2026, 22:10 UTC

Ganancias

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 may 2026, 22:09 UTC

Ganancias

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 may 2026, 22:09 UTC

Ganancias

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 may 2026, 22:08 UTC

Ganancias

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 may 2026, 22:07 UTC

Ganancias

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 may 2026, 22:06 UTC

Ganancias

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 may 2026, 22:06 UTC

Ganancias

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 may 2026, 22:05 UTC

Ganancias

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 may 2026, 22:04 UTC

Ganancias

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 may 2026, 22:04 UTC

Ganancias

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 may 2026, 22:04 UTC

Ganancias

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Comparación entre iguales

Cambio de precio

Ardelyx Inc previsión

Precio Objetivo

By TipRanks

151.13% repunte

Estimación a 12 Meses

Media 16.6 USD 151.13%

Máximo 19 USD

Mínimo 13 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ardelyx Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Ardelyx Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

3.62 / 3.95Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bearish.

Recent bearish events outweigh bullish events.

Sentimiento

By Acuity

64 / 346 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.